214 related articles for article (PubMed ID: 6539165)
1. Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma.
Berry JP; Pauwells C; Tlouzeau S; Lespinats G
Cancer Res; 1984 Jul; 44(7):2864-8. PubMed ID: 6539165
[TBL] [Abstract][Full Text] [Related]
2. Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats.
Baldew GS; van den Hamer CJ; Los G; Vermeulen NP; de Goeij JJ; McVie JG
Cancer Res; 1989 Jun; 49(11):3020-3. PubMed ID: 2720662
[TBL] [Abstract][Full Text] [Related]
3. Cis DDP in combination with selenium and sulfur. Subcellular effect in kidney cells. Electron microprobe study.
Berry JP; Lespinats G
J Submicrosc Cytol Pathol; 1988 Jan; 20(1):59-65. PubMed ID: 3370622
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
5. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
Konstantinov S; Topashka-Ancheva M; Karaivanova M; Zoneva G; Galova I
Neoplasma; 1994; 41(5):253-8. PubMed ID: 7854494
[TBL] [Abstract][Full Text] [Related]
6. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
Vadi H; Drewinko B
Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
[TBL] [Abstract][Full Text] [Related]
7. Combination of N-methylformamide with cis-diamminedichloroplatinum (II) in murine mammary carcinoma: importance of timing.
Iwakawa M; Tofilon PJ; Arundel C; Milas L
Cancer Res; 1989 Apr; 49(7):1640-3. PubMed ID: 2924311
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
Fan Z; Baselga J; Masui H; Mendelsohn J
Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640
[TBL] [Abstract][Full Text] [Related]
9. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
Baldew GS; McVie JG; van der Valk MA; Los G; de Goeij JJ; Vermeulen NP
Cancer Res; 1990 Nov; 50(21):7031-6. PubMed ID: 2208170
[TBL] [Abstract][Full Text] [Related]
10. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
11. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
12. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II).
Esposito M; Viale M; Vannozzi MO; Zicca A; Cadoni A; Merlo F; Gogioso L
Toxicol Appl Pharmacol; 1996 Oct; 140(2):370-7. PubMed ID: 8887454
[TBL] [Abstract][Full Text] [Related]
13. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice.
Naganuma A; Satoh M; Imura N
Cancer Res; 1987 Feb; 47(4):983-7. PubMed ID: 3802104
[TBL] [Abstract][Full Text] [Related]
14. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antitumor activity of a new cis-diammineplatinum (II) complex containing procaine hydrochloride.
Cafaggi S; Esposito M; Parodi B; Vannozzi MO; Viale M; Pellecchia C; Fulco RA; Merlo F; Zicca A; Cadoni A
Anticancer Res; 1992; 12(6B):2285-92. PubMed ID: 1295476
[TBL] [Abstract][Full Text] [Related]
16. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents.
Montine TJ; Borch RF
Cancer Res; 1988 Nov; 48(21):6017-24. PubMed ID: 2458831
[TBL] [Abstract][Full Text] [Related]
17. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
18. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia.
Howell SB; Taetle R
Cancer Treat Rep; 1980; 64(4-5):611-6. PubMed ID: 7191778
[TBL] [Abstract][Full Text] [Related]
19. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling.
Baba H; Siddik ZH; Strebel FR; Jenkins GN; Bull JM
Cancer Res; 1989 Dec; 49(24 Pt 1):7041-4. PubMed ID: 2582445
[TBL] [Abstract][Full Text] [Related]
20. Response of murine tumors to matrix-associated cisplatin intratumoral implants.
Yu NY; Conley FK; Luck EE; Brown DM
NCI Monogr; 1988; (6):137-40. PubMed ID: 3352755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
